Researchers unveiled a generative AI model designed to predict protein-protein interactions at atomic scale, aiming to improve how scientists identify and engineer binding partners for therapeutic development. Because many drug classes—including antibody therapies and biologics—depend on specific protein interactions, the approach targets a core bottleneck in discovery. The work frames protein-protein interaction prediction as a way to expand options for treating disease by enabling more accurate hypotheses about how proteins physically contact and function together. The article describes the model’s intended use for both prediction and engineering of interaction interfaces. For drug developers, the immediate value is tighter iteration in early-stage target and construct optimization, with the potential to reduce experimental churn during lead identification and preclinical design.